Skip to content
FY'25FY'24FY'23FY'22
Profitability
Gross margin97.9%+1.2pp96.7%+4.6pp92.1%-2.2pp94.4%
Operating margin-12.8%+126pp-138.9%+128pp-267.2%+24.9pp-292.2%
Returns
Return on invested capital-96.2%+151pp-247.2%+176pp-423.6%-77.6pp-346%-226pp
Efficiency
Asset turnover0.8×+0.5×0.3×+0.1×0.2×0.0×0.2×
Liquidity
Current ratio2.7×+0.7×2.1×-1.4×3.5×0.0×3.4×-1.3×
Leverage
Debt-to-equity0.1×-1.4×1.5×+1.4×0.1×-0.6×0.7×+0.6×
Per Share
Book value per share$1.29+71.9%$0.75-72.3%$2.70+302%$0.67-86.7%
Valuation
Market capitalization$3.42B+125%$1.52B+121%$687.51M-49.1%$1.35B-31.1%
Price / sales+0.5×6.5×+1.8×4.7×-7.6×12.3×
Price / book29.8×+4.1×25.7×+22.2×3.4×-28.1×31.5×+25.0×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Travere Therapeutics, Inc.'s profit margins?
Travere Therapeutics, Inc. (TVTX) runs a 98.6% gross margin and a -10.6% operating margin, with a -20.3% net margin.
Where do Travere Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Travere Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.